Azienda Unita Sanitaria Locale Di Bologna
- Address
- Via Altura 3, 40139 Bologna, Italy
Azienda Unita Sanitaria Locale Di Bologna - Clinical Research Center
The Azienda Unita Sanitaria Locale Di Bologna is a comprehensive clinical research center conducting innovative trials across multiple therapeutic areas. The facility demonstrates particular expertise in oncology research, with active investigations in glioblastoma, breast cancer, head and neck cancer, meningiomas, follicular lymphoma, and melanoma, employing cutting-edge immunotherapy combinations and targeted therapeutic approaches.
- Neurological disorders including Parkinson's disease, multiple sclerosis, myasthenia gravis, Huntington's disease, and epilepsy
- Gastroenterological conditions such as inflammatory bowel disease (Crohn's disease and ulcerative colitis) in both adult and pediatric populations
- Rare and genetic diseases including spinal muscular atrophy, congenital adrenal hyperplasia, laminopathies, and mitochondrial diseases
- Hematologic malignancies and immunological disorders, featuring advanced CAR-T therapy and biosimilar development
The center actively participates in pediatric clinical research, conducting studies in children and adolescents with conditions ranging from insomnia and myasthenia gravis to inflammatory bowel disease. Additional research areas include cardiovascular studies, sleep disorders (narcolepsy), chronic rhinosinusitis, venous thromboembolism, and endocrine disorders such as microprolactinomas. The institution's diverse portfolio reflects its commitment to advancing treatment options across a broad spectrum of medical conditions through rigorously designed clinical trials.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 10 therapeutic areas and 15 of 29 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Unita Sanitaria Locale Di Bologna
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 29 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 5,7-Dimethyl-N-((1R,4R)-4-(Pentyloxy)Cyclohexyl)Pyrazolo[1,5-A]Pyrimidine-3-Carboxamide | 1 | Unknown | 2023-07-21 | 2023-07-21 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.